Table 1.
Neuropilin levels correlated with responsiveness/resistance to cancer therapies.
| Therapy | NRP1 Levels Correlate with | References | NRP2 Levels Correlate with | References |
|---|---|---|---|---|
| Radiotherapy | low responsiveness (non-small cell lung cancer) | [30] | - | - |
| Chemotherapy (5-fluorouracil) | low responsiveness (pancreatic, non-small cell lung, and prostate cancers) | [31,32] | high responsiveness (colorectal adenocarcinoma) | [34] |
| Chemotherapy (platin-derived drugs) | low responsiveness (non-small cell lung, prostate, and oral squamous cell carcinoma) | [32,33] | high responsiveness (colorectal adenocarcinoma) | - |
| Chemotherapy (paclitaxel) | low responsiveness (non-small cell lung and prostate cancers) | [32] | - | - |
| Chemotherapy (gemcitabine) | low responsiveness (pancreatic cancer) | [31] | - | - |
| Chemotherapy (docetaxel) | - | low responsiveness (prostate and pancreatic cancers) | [36] | |
| Chemotherapy (doxorubicin) | low responsiveness (breast cancer) | [35] | - | - |
| EGFR inhibitor (cetuximab) | secondary resistance (pancreatic cancer) | [41] | - | - |
| Androgen-targeted therapies (ATTs) | secondary resistance (prostate cancer) | [42] | - | - |
| cMET inhibitor (JNJ38877605) | secondary resistance (gastric and lung cancer) | [43] | high responsiveness (lost upon acquired resistance) (gastric and lung cancer) | [44] |
| B-Raf inhibitor (PLX-4720) | secondary resistance (melanoma) | [43] | - | - |
| Her2 inhibitor (lapatinib) | secondary resistance (breast cancer) | [43] | - | - |
| anti-VEGF (bevacizumab) | low responsiveness (gastric cancer) | [37] | low responsiveness (bladder cancer) | [38] |
Table 1 lists reported correlations between high expression levels of NRP1 or NRP2 and responsiveness or resistance to different kinds of cancer therapies. Tumor samples derived from treated patients were analyzed in part of the studies (by immunohistochemistry or mRNA qPCR); in other cases, gene expression was engineered in cultured cancer cells subjected to therapy. In parentheses, the implicated drugs (in first column) and tumor types (in second and fourth column) are specified; “-“ stands for “not reported”.